Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...
Jennifer Bisset was a senior editor for CNET. She covered film and TV news and reviews. The movie that inspired her to want a career in film is Lost in Translation. She won Best New Journalist in 2019 ...
Sorry to burst your bubble right off the bat, but the show hasn’t even been renewed yet. While Welcome to Derry had a strong start, that number quickly fell off in subsequent episodes. That said, it’s ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
REPL is down today, likely because the market realizes FDA approval may not come until Q2 2026, even in the best case. Based on the FDA’s previous comments about needing a “more adequate and ...
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...
Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...
There is no better way to protect the art you love and ensure it is always available for enjoyment than physical media. We know some people enjoy keeping tabs on the licensing agreements, expiration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results